Introduction
Angiogenesis is an important physiological event, consisting of the formation of new blood vessels from the preexisting microvasculature network, and is also involved in pathological processes such as inflammation, tumor growth, and metastasis. Tumor angiogenesis plays ak ey role in cancer development, as neovascularization is necessary to supply oxygen and nutrients in order to support tumor cell proliferation.
[1] Substances capable of blocking tumor-related angiogenesis and, therefore, retarding cancer progression are termeda ntiangiogenic agents.
Angiogenesis is regulated by an umber of receptors, whose expression is relatedt ot he conditions of the cell environment, such as pH and supply of oxygen and nutrients.
[1c] Among the proteins involved in the angiogenic process, integrins play an important role by promoting endothelial cell attachment and migration onto the surrounding extracellular matrix,c ell-to-cell interaction, and intracellular signal transduction. [2] Integrins are heterodimeric glycoproteins composed of two noncovalently associated a and b transmembrane subunits,w hich recognize and bind their ligandst hrough contiguous tripeptides equences. The recognition motif Arg-Gly-Asp (RGD) allows endogenous ligands to interactw ith several integrins( e.g. a V b 3 , a V b 5 , and a 5 b 1 )t hat are very important for tumor progression, metastasis,a nd angiogenesis. [3] An umber of peptide and peptidomimetici ntegrin ligands containing the RGD sequence have been developed, some of which display as trong affinity towards these receptors.
[4] X-ray analysiso fi ntegrin a v b 3 cocrystallized with the cyclic RGD pentapeptide cyclo-[Arg-Gly-Asp-dPhe-N(Me)-Val],C ilengitide, provided the structural basis to rationalize the observed binding properties.
[5] Activity and selecAd ual-action ligand targeting both integrin a V b 3 and vascular endothelial growth factor receptors (VEGFRs), was synthesized via conjugation of ac yclic peptidomimetic a V b 3 Arg-Gly-Asp (RGD) ligand with ad ecapentapeptide. The latter was obtained from ak nown VEGFR antagonist by acetylation at the Lys13 side chain. Functionalization of the precursor ligandsw as carried out in solution and in the solid phase, affording two fragments:a na lkyne VEGFR ligand andt he azide integrin a V b 3 ligand,w hich were conjugatedb yc lick chemistry.C ircular dichroism studies confirmed that both the RGD and VEGFR ligand portionso ft he dual-action compound substantially adopt the biologically active conformation. In vitro binding assays on isolated integrin a V b 3 and VEGFR-1s howed that the dual-action conjugate retains ag ood level of affinity for both its target receptors, althoughw ith one ordero fm agnitude (10/20 times) decreasei np otency.T he dual-action ligand strongly inhibited the VEGF-induced morphogenesis in Human Umbilical Vein Endothelial Cells (HUVECs). Remarkably,i ts efficiency in preventing the formation of new blood vessels was similar to that of the originali ndividual ligands, despite the worse affinity towards integrin a V b 3 and VEGFR-1.
tivity of these integrin ligands are linked to an extended conformationo ft he RGDs equence, with ad istance of about 9 between the C b atom of aspartic acid and argininer esidues, whose side chainsf orm an "electrostatic clamp" [5] crucial for ligand binding to the integrin receptor.
Our research group has recently reported al ibrary of new cyclic RGD peptidomimetic integrin ligands, containing bifunctional diketopiperazine (DKP) scaffolds, [6] that displayed low nanomolar IC 50 values in inhibiting the binding of biotinylated vitronectin to integrin a V b 3 .I nvitro biological studies performed on compound 1 (Figure 1 ) showedt hat this ligand is able to inhibit angiogenesis in HumanU mbilical Vein Endothelial Cells (HUVEC), both under basal conditions and in the presence of pro-angiogenic growth factors [7] or of pro-inflammatory chemokine interleukin-8 (IL-8). [8] The observed antiangiogenic activity was likely due to the disruption of endothelialc ell-extracellular matrix attachment, induced by integrin engagement by compound 1.This was further confirmed by the inhibition of the phosphorylation of Akt, as erine/threonine-specific protein kinase that plays ak ey role in the regulation of vascular homeostasis and angiogenesis. Unlike angiogenesis, other parameters such as cell viability, cell proliferation, and mRNA levels of a V , b 3 ,o rb 5 integrin subunits were not affected by the administration of compound 1. [8, 9] Other cell surface receptors besides integrins are involved in tumor angiogenesis, and the pathways mediated by the different receptors are deeply intertwined. Such a" crosstalk" stimulates the angiogenic process through both direct and indirect association of the involved receptors. Interactions between integrins and vascular endothelial growth factor receptors (VEGFRs) have been investigated and suggested to be crucial for tumor growth and invasion.
[10] VEGFRs are members of the receptor tyrosine kinase (RTK)s uperfamily, and their dimerization anda ctivation are induced by the binding of endogenoush omodimericv ascular endothelial growth factors (VEGF) to the receptor extracellulard omain. The biological activityo ft he VEGF-VEGFR system is closely related to tumor angiogenesis and progression:t he hypoxicc onditions presenti nt umors induce both VEGF gene expression and upregulation of VEGFRs. [11] Small molecule inhibitors of VEGF-A receptor tyrosine kinase (receptor intracellulars egments)h ave been shown to inhibit the biological functiono ft his growth factor and are currently being used as drugs (Sorafenib and Sunitinib) for antiangiogenic therapy. [12] Other inhibitors of the VEGF's biological activity interactw ith the VEGFRs' extracellular segment,a nd most members of the latter family are peptides or peptidomimetics. Among them,i ti sw orth mentioning the peptoid ligandsd eveloped by Kodadek and co-workers, [13] the helical peptides derived from VEGF, [14] andV ammin hotspots, [15] a1 7-aminoa cid cyclopeptidet hat was isolated from ap hage display library. [16] The reported colocalization of integrin a V b 3 and VEGFR on the surface of HUVEC upon VEGF stimulation demonstrates that a" crosstalk" between theser eceptors occurs.
[10f] Following these findings, in ap ioneering study,C ochran and co-workers reported that ad ual specific fusion protein was able to bind simultaneously integrin a V b 3 andV EGFR-2, and to inhibitV EGFmediated capillary tubef ormation in HUVECa nd murine blood vessel formation within implanted Matrigel plugs. [17a] Inspired by this contribution, we speculated that ad ual-action integrin-VEGFR small molecule ligand could also represent an ovel antiangiogenic and antitumor strategy offering more effective multiple targeting to tumor cells and tumor vasculature.
[17b] We thus designed an ew dual-action ligand (compound 5 in Figure 2 ) targetingi ntegrin a V b 3 and VEGFR. As integrin binding moiety,w ee xploited cyclo[DKP-RGD]-CH 2 NH 2 (2) ( Figure 1 ), af unctionalized analog of ligand 1 that we had previously used for conjugation to paclitaxel [18] and SMAC mimetic molecules. [19] As VEGFRl igand moiety we selected the a-helical decapentapeptide 3 (Figure 2) , recently reported by D'Andrea and co-workers, [14] because of its simple preparation and efficacy in inhibiting angiogenesis in vivo. However,f or conjugation to compound 2 we employed compound 4 (Figure 2 ), ad erivative of 3 acetylated at the Lys13 side chain, [20] in order to avoid [14b]
Accordingly,w hile both positions could in principleb ee xploited for conjugation, in this paperw eu sed the N-terminal Lys1 side chain.
Results and Discussion
Synthesis of the dual-action compound 5
The dual-action ligand 5 (Figure 2 ) was obtained from the two fragments 6 and 7,t hat were joined by copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction (Scheme 1). Alkyne 6 was obtainedf rom the resin-supported peptide 8, base, obtaining fragment 6.F ragment 7 was prepared starting from the commercially availableb ifunctionalP EG 8 compound 10 ( Figure 3A ), which was selected because of its monodisperse structure profile. [21] Amino azide 10 was first elongated with succinic anhydride, affording the azido acid 11. Cyclo[DKP-RGD]-CH 2 NH 2 2 (Figure 1 ) was coupled with the spacer 11 in acetonitrile/phosphate buffer, controlling the pH of the mediumi no rder to have the free benzylic amine of 2 acting as nucleophile.F inally,t he synthesis of the dual-action ligand 5 was achieved by coupling fragments 6 and 7 on solid phase via CuAAC reactioni nt he presence of copper iodide and sodium ascorbate, and then by cleaving the adduct 12 from the resin.
The 39-atom-long linker system of conjugate 5 ( Figure 3B )i s of length commensurate with the linker used by Cochran and co-workersf or their dual-specific proteins (14 amino acid residues, that is, 42 atoms,b etween the two ligand moieties). [17a] The decapentapeptide 4 (Figure 2 ), used as ar eference com- Scheme1.Reagents and conditions:a)SPPS:1)25% piperidine in DMF,2)Fmoc-AA-OH (4 eq), DIC, HOAt, DIPEA, DMF,3 )25% Ac 2 Oi nDMF;b )CH 2 Cl 2 /TIS/TFA 94:5:1 v/v/v,r .t.,122min;c)4-pentynoic acid, HATU, HOAt, DIPEA, DMF,r .t.,o/n;d)succinic anhydride, DMAP,DIPEA, CH 2 Cl 2 ,r .t.,18h,96%;e )N-hydroxysuccinimide, DIC, DMF, r.t.,2h, then 2,C H 3 CN, phosphate buffer,pH7.3-7.6,08C, 18 h, 65 %o ver 2steps;f )6 + 7,CuI, sodium ascorbate, DIPEA, DMF,72h,r .t.; g) TFA/EDT/H 2 O/TIS 94:2.5:2.5:1 v/v/v/v,3h, r.t.,5%( 4,over 16 steps) and6%( 5,over1 9s teps).M tt = 4-methyltrityl.
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Structural investigation of the synthesized compounds
The circulard ichroism (CD) spectrumo fp eptide 4 measured in water (Figure 4 ) is consistentw ith that published by D'Andrea and co-workers for the parent peptide 3. [14] The positiona nd the intensities of the two negative maxima indicate the presence of ar elevantp opulation of a-helicals tructures. However, the negative maximum of the amide p!p*e lectronic transition, located at 203 nm, is significantly blue-shifted with respect to the canonical position (208 nm) of an a-helicalc onformation. This finding, together with the intensity decrease of the band at about 222 nm, can be safely assigned to an onnegligible participation of unordered conformations, also called "polyprolinet ype-II". We extended our analysis to two additional solvents, namely trifluoroethanol( TFE) and methanol, roughlym imicking the hydrophobic biological environment in which the peptidew ould probablyd isplay its action. [22] These CD spectra (Figure 4 ) are characterized by two negative maxima typicalo fa na-helical conformation. This increase in the helical content, moving from water to the alcoholic solvents, clearly indicates that peptide 4 is not very rigid, as its 3D-structure is highly dependento nt he environment. The same is true for the parent peptide 3,w hose CD spectra undergo ap arallel modification in the cited solvents (see the Supporting Information).
These conclusions, based on the analysiso ft he amide absorptionr egion (190-250 nm), must be taken with caution as the aromatic chromophores of Tyra nd Trpm ay contribute in an unpredictable way.I ndeed, despite being achiral, they might display induced CD signals, whose intensities depend on the rigidity of the molecule. To evaluatet his possible interference, we analyzed the region above 250 nm, where the amide absorption is negligible. In the UV absorption spectra of peptides 3 and 4,r ecorded at the same peptide concentration of the CD measurements, ab and centered at 275 nm is clearly visible in all solvents investigated (data not shown). Conversely, in the corresponding CD spectra,n ob ands above 250 nm could be detected. On this basis, we can conclude that the contribution of the aromatic moieties to the CD curves is marginal.
The ratio R between the ellipticity values (q)o ft he two negative maxima( R = [q] 222 /[q] 208 )c an be used to discriminate the contribution to the CD curves of a-and 3 10 -helical structures. [22] In particular,a nR value smaller than 0.5 is diagnostic of an important contribution from 3 10 -helical conformations, while av alue closer to 1i si ndicative of an a-helicals tructure. The R value of peptide 4 in water is not significant because, as stated above,t he wavelengths of the negative maxima in this solvent are too far from those of ac anonical helix. In TFE and in methanol the R values are 0.84 and 0.86, respectively,t hus highlighting the presence of ap redominantly a-helicalc onformation.
The CD spectra in water of compounds 2 and 7 are shown in Figure5.T he two curves have trends usually attributed to type b folding, in particular b-turn type II, characterized by two maxima: ap ositive maximuma t% 203 nm and an egative one at % 226 nm. Similarspectra were observed in cyclic tripeptides known to adopt b-turn structures. Interestingly,t he relatively modest differences of the two curvess uggest that the PEG 8 moiety does not alter significantly the structure of compound 7 with respecttot he precursor molecule 2.
In ap reviousw ork, this class of compounds was already demonstrated via NMR and computational studies to adopt a b-turn-like conformation (Figure 6 ). [6] In Figure 7 , the CD spectrum of 5 and the spectrum obtained by the algebraic sum of the spectra of 4 and 7 are reported.
As the two spectra display rather similar features (band position, sign, and intensity), we tentatively concludet hat no dramatic conformational changes occur.H owever,w ec annote xclude the intervention of minor but significant structure modifications. The CD lineshape of the dual ligand 5 changes when water is replaced by either TFE or methanol ( Figure 8 ), somehow mirroring the behavior of 4 (Figure 4) . Therefore, this www.chemistryopen.org change in the CD pattern should be ascribed mainly to peptide 4.I ndeed, in ac omparative analysisw eo bserved that the conformation of the cyclic, constrained, RGD ligand is not affected by the solvent( Supporting Information). In summary, the conformational behavior of the two isolated ligands is not substantially alteredu pon conjugation in the dual ligand 5. Yet, even minor structural changes can somehow impact on highly stereospecific activities such as receptor binding.
Biological studies

In vitro binding assays on isolated integrins and VEGF receptor
The binding of the dual-action ligand 5 to the isolated integrin and VEGF receptorsw as measured. In the case of integrins, the ability of compound 5 to inhibitb iotinylated vitronectin binding to the purified a V b 3 and a V b 5 extra-cellular integrin domains (IC 50 )w as determineda nd compared with that of reference compounds 1
[6b] and cyclo[RGDfV] 13 ( Figure 9 ). [23] Similar to its parentl igand 1,c onjugate 5 showed ar emarkable selectivity for integrin a V b 3 compared with a V b 5 (Table 1 ). In the case of 5,t he affinity for integrin a V b 3 remained in the nanomolar range, although it was about2 0times worse than that of unconjugated ligand 1,p ossibly because of the increaseds teric hindranceo ro fi nterference with the decapentapeptideVEGFR ligand. These binding experiments demonstrate that the cyclo[DKP-RGD] moiety retains its ability to bind to the a V b 3 integrin receptor, even after conjugation.
The conjugate ligand 5,t ogether with the VEGFR ligands 3 and 4,w ere also evaluated for their ability to compete with biotinylated VEGF 165 for the binding to the extracellular domain (D1-D7) of recombinant VEGFR-1. The test was accom- www.chemistryopen.org plished according to the procedure reported by Vidal, Inguimbert, and co-workers. [15, 24] Unlabelled VEGF 165 ,used as reference compound, showed an IC 50 value of 146 pm,c omparable with the value reported by the same authors. [24] Unfortunately,f or compounds 3 and 4,i tw as not possible to obtain ad ose-responsec urve because, at high concentrations (above0 .1 mm), the wells showeda na nomalouslyh igh chemiluminescence readout (even higher than that of the positive control). In this way,w ec ould only observe the initial inhibition of the binding of biotinylated VEGF 165 by compounds 3 and 4 at 10 mm concentration.T he reasons for this behavior are currently unclear,a nd modifications in the sample preparation protocol (e.g. change of the amount of dimethylsulfoxide, DMSO,u sed for solubilizing the peptide) did not solve the problem. It shouldb en oted that the IC 50 binding value of compound 3 to VEGFR-1 reported in the literature was not determined with this kind of competitive bindingp rotocol. Rather,t he affinity value was measured by NMR titration on VEGFR-1 D2 (K d = 46 mm).
[14b]
The dual-action compound 5 did not show this anomalous behavior in competitive binding assay,a nd its affinity towards VEGFR-1 was determined as 57 % AE 10 %i nhibition at 500 mm concentration. Therefore, conjugate 5 is about ten times less potent than peptide 3 (or its acetylated derivative 4)i ni nhibiting VEGF binding to VEGFR-1. In summary,d ual-action compound 5 showed affinity towards both its receptor targets (integrin a V b 3 and VEGFR-1), although with one order of magnitude (10/20 times) loss of potency.
In vitro morphogenesis assays on HUVEC
HUVECs represent av alid in vitro model providing seminal insights into the cellular and molecular eventsl eadingt on eovascularization in response to inflammation and hypoxia in cancer,i schemic events, and in embryogenesis. [25] Integrins a V b 3 and a V b 5 are expressed on HUVEC [26] and these human endothelial-derived cells represent as uitable model to investigate the effects of integrinl igandsona ngiogenesis.
To assess the activity of the compounds targeting only one cell surfacer eceptor,n amely integrin ligand 1 and VEGFR ligands 3 and 4,a sw ell as the dual-action ligand 5,H UVEC were incubated with thesec ompounds under basal (absence of stimuli)o rs timulated (VEGF 165 )c onditions. Under basal conditions,H UVEC did not show any network formation, butt he addition of VEGF 165 induceds ignificant morphogenesis (Figure 10 A) . The addition of integrin ligand 1,V EGFR ligands 3 and 4 and dual-action ligand 5 markedly decreased the new capillaryn etwork formation( see for instance Figure 10 B) whereas the addition of negative control 14 (Ac-Lys-Gln-MetTyr-Leu-Glu-Leu-Gly-Tyr-Ala-Thr-Ile-Lys-Trp-Leu-amide), ap eptide containing the same amino acids as 3 and 4 but in as crambled sequence, didn ot affect morphogenesis to as ignificant extent (Figure 10 C) .
Ad ose-responses tudy ( Figure 11 )r evealed that all the tested ligands display as imilar profileo fa ctivity,r educing the morphogenesisa lready at nanomolar concentration. This effect is in agreement with previousr eports using ligand 1 on HUVEC, albeit with differents timuli, [8] and ligand 3. [14] Interestingly,a lso peptide 4,b earing an acetyl group at the nitrogen atom of Lys13 side chain, provedc apable of inhibiting angiogenesisw ith an efficacy similar to that of its parent compound 3 (Figure 11 C) . Therefore, Lys13 side chain acetylation does not affect significantly the biological properties of peptide 3.T he dual-action compound 5 (Figure 11 D) proved comparably active, inhibiting morphogenesis in HUVECs with as imilar concentration profile and effect:a ll the ligandst ested decreased the length of branches in newly formed vessels to a4 0% with respectt ot he stimulation with VEGF ( Figure 12 ). In addition, the co-administration of ligands 1 and 4 wasi nvestigated (Figure 11 E) . Also in this case no differencei nc oncentrationa nd effect profile could be noticed. Finally,t he scrambled peptide 14 (negative control),t ested at the 1 mm concentration, did not significantly affect VEGF-induced morphogenesis (82 % AE 21 %o fVEGF alone, calculated probability value p > 0.05) and confirmed that the effects observed for all the other compounds are due to their specific interaction with the targeted receptors. The overall pictured esigned by these data refers to av ery active set of ligandsw hich, once combined in ad ualaction system fully retain the antiangiogenic activity.R emarkably,t he efficiency of the dual-action ligand 5 in preventing the formation of new blood vessels was comparable to that of ligands 1 and 4,s ingly or jointly administered, despite its worse affinity towards integrin a V b 3 and VEGFR-1 (one order of magnitude loss of potency). This finding might be interpreted as the result of as ynergy between the two covalently linked binding motifs, in analogy with the resultso nf usion proteins in which the mutated protein containing both the VEGFR and integrin binding sequences displayed am ore pronounced effect of morphogenesis inhibition in HUVEC. [17a] 
Conclusions
Tumor angiogenesis is ac rucial phenomenonf or cancer development and metastasis, and is regulated by an umber of cell surfacer eceptors, such as integrin a V b 3 and VEGFRs,w hich are known to specifically interact (receptor-receptor "crosstalk"). A dual-action ligand 5 was synthesized via conjugation of the potent peptidomimetic a V b 3 RGD ligand 1 with the decapentapeptide 4,aderivative acetylateda tt he Lys13 side chain of knownp eptide 3,aV EGF receptor antagonist with antiangiogenic activity.L igand 5,t argeting both integrin a V b 3 and VEGFRs, was designed with the aim of inhibiting both recep- ) + 5 (1 mm); C) VEGF 165 (10 ng mL À1 ) + 14 (1 mm). Images were elaborated by phase-contrast microscopy using afluorescencemicroscope. Framesa re approximately 10 mmw ide 1 0mmtall.
ChemistryOpen 2015, 4,633 -641 www.chemistryopen.org tors and possibly blocking their "crosstalk". The secondary structure of dual-action ligand 5 was studied by circulard ichroism spectroscopy,a nd both the RGD portion and the decapentapeptide in the conjugate were found to substantially retain their respective conformations. However, even minor structural changes can somehow impact on highly stereospecific activities such as receptor binding.
Dual-action ligand 5 was tested in vitro for its ability to bind to isolatedi ntegrin a V b 3 and VEGFR-1 receptors. Conjugate 5 showeda ffinity towards both its receptor targets (integrin a V b 3 and VEGFR-1), although with one order of magnitude (10/20 times) loss of potency compared to ligands 1 and 4, targeting only one receptor. Conjugate 5 showed ap otent antiangiogenica ctivity in VEGFstimulated morphogenesis assayso nHUVEC. Remarkably,i ts efficiency in preventing the formationo fn ew blood vessels was similar to that of ligands 1 and 4,s ingly or jointly administered,d espite its worse affinity towardsi ntegrin a V b 3 and VEGFR-1. This finding might be interpreted as the result of asynergy between the two covalently linked binding motifs. [17a] However,i nt his particularcase (no real advantage in the morphogenesis assays overl igands 1 and 4), the extra effort for the synthesis of conjugate 5 is not justified, and further investigations are necessary to:1 )design and develop more efficient dualaction compounds targeting integrins andV EGFR and 2) confirm the beneficial effect of ad ual ligand with in vivoe xperiments.
Experimental Section
The detailed procedure for the synthesis of compounds 1 and 2, and for conjugation of 2 to other molecular entities was previously described. [6b, 18] Solid phase peptide synthesis (SPPS):The SPPS was accomplished using the semiautomatic synthesizer Biotage Initiator (Uppsala, Sweden) assisted by microwaves;f luorenylmethyloxycarbonyl (Fmoc) strategy and Rink amide MHBA resin (100-200 mesh;l oading:0 .5 mmol g À1 )w ere used. Each coupling step consisted of 1) activation of the Fmoc-protected amino acid, 2) addition of the www.chemistryopen.org activated amino acid to the resin in the synthesizer,inorder to perform the coupling reaction, and 3) capping, deprotection, and washing steps.
Resin preparation and storage:B efore starting the SPPS, the resin was swollen in dimethylformamide (DMF) (3.0 mL) at r.t. for 45 min, then the solvent was drained. Twod eprotection steps were carried out adding 25 %p iperidine in DMF (3.0 mL for each step) to the beads:t he reaction was performed at r.t. under inert atmosphere for 5min and 15 min for the first and the second deprotection step, respectively.T he resin was then washed with DMF.A tt he end of each step, the liquid phase was drained. Whenever it was necessary to stop the SPPS, the beads were stored in DMF (2-3mL) at À20 8C, with the terminal amino group of the peptide left Fmoc-protected.
General procedure for Fmoc-AA-OH activation and coupling cycle:T oasolution of the desired Fmoc-AA-OH (4.0 eq with respect to the resin) in DMF (3.5 mL) DIC (4.0 eq), HOAt (4.0 eq) and DIPEA (8.0 eq) were added successively at 0 8C, under stirring and inert atmosphere. After 25 min, the reaction mixture was added to the resin in the reaction vessel of the synthesizer,a nd ac ycle of coupling-capping-deprotection-washing was effected. At the end of the cycle, it is possible to add another residue or to effect acapping-washing cycle if the peptide sequence is complete.
General procedure for Kaiser test:Afew resin beads were taken and put in ag lass test tube. The beads were washed with EtOH, then three drops of each of the following solutions were added: 1) % 80 %p henol in EtOH, 2) KCN in pyridine [prepared by diluting a0 .1 mm aqueous solution of KCN with pyridine (2 % v/v)],a nd 3) 6% ninhydrin in EtOH. The mixture was shaken and heated in aw ater bath. The resin beads and the solution turned dark blue when af ree primary amine was present (positive result). Resin beads and solution maintained their yellow color when free primary amino groups were absent (negative result).
General procedure for final cleavage and deprotection:T he protected-on-beads peptide was swollen first with DMF (3.5 mL), then with CH 2 Cl 2 (3.5 mL). The beads were treated three times with the cleavage cocktail 94:2.5:2.5:1 TFA/H 2 O/EDT/TIS (v/v/v/v). After 1h, the liquid was filtered off under nitrogen flow and collected in ar ound-bottom flask. The combined filtered fractions were concentrated and poured in cold diethyl ether,p rovoking precipitation of the product. Diethyl ether was removed with as yringe, affording the crude product, which was purified with reverse-phase HPLC.
Circular dichroism spectroscopy:The CD measurements were registered on aJ asco J-715 instrument (Easton, USA) with Hellma 0.1 cm quartz cell in milliQ H 2 Oa ss olvent. The spectra were elaborated with Origin and the Jasco instrument associated software. The values are reported as total molar ellipticity [q] T (deg cm 2 dmol
À1
).
Solid-phase receptor-binding assays on integrin receptors:P urified a V b 3 and a V b 5 receptors (Chemicon International, Inc.,T emecula, USA) were diluted to 0.5 mgmL À1 in coating buffer containing 20 mmol
A na liquot of diluted receptors (100 mL/well) was added to 96-well microtiter plates (NUNC MW 96F Maxisorp Straight) and incubated overnight at 4 8C. The plates were then incubated with blocking solution (coating buffer plus 1% bovine serum albumin) for additional 2hat r.t. to block nonspecific binding followed by 3h-incubation at r.t. with various concentrations (10 À12 -10 À5 m)o ft est compounds in the presence of 1 mgmL À1 vitronectin biotinylated using EZ-Link Sulfo-NHS-Biotynilation kit (Pierce, Rockford, USA). After washing, the plates were incubated for 1h at r.t. with streptavidin-biotinylated peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 min incubation with Substrate Reagent Solution (100 mL, R&D Systems, Minneapolis, USA) before stopping the reaction by addition of 2 n H 2 SO 4 (50 mL) Absorbance at 415 nm was read in aS ynergy HT Multi-Detection Microplate Reader (BioTek Instruments, Inc.,W inooski, USA). Each data point is the result of the average of triplicate wells and was analyzed by nonlinear regression analysis with Prism software version 5( GraphPad Software, Inc.,L aJolla, USA).
Solid-phase receptor-binding assays on VEGFR-1:T he surface of white high-binding 96-well microplates (Corning Life Sciences, Netherlands) was coated with of phosphate-buffered saline solution (100 mL, PBS, pH 7.4) containing 200 ng mL À1 of VEGFR-1 ECD/ Fc chimera (R&D Systems, Minneapolis, USA) and incubated overnight at 4 8C. After three washes with PBS 0.1 %, (150 mL, v/v) Tween 20 (buffer A), the plate was blocked by PBS (160 mL) with 3% (w/v)o fB SA and incubated at r.t. for 2h.T he plate was washed three times with buffer A. Then, 100 mLo fas olution of btVEGF 165 at 131 pm (5 ng mL À1 )and the tested compounds at various concentrations diluted in PBS containing 5% DMSO were added to each well. After 3hat 37 8C, the plate was washed three times with buffer Aa nd streptavidin-horseradish peroxidase (100 mL) diluted at 1:1000 in PBS containing 0.1 %( v/v)T ween 20 and 0.3 %( w/v)B SA were added per well. After 1h of incubation at r.t.,t he plate was washed five times with buffer A( 150 mL), and SuperSignal West Pico Chemiluminescent Substrate (100 mL, Pierce, Rockford, USA) was added. The remaining bt-VEGF 165 was detected by chemiluminescence, which was quantified with aS ynergy HT Multi-Detection Microplate Reader (BioTek Instruments, Inc.,W inooski, USA). The percentages of btVEGF 165 displacement were calculated by the following formula:p ercentage of displacement = 100 [1À(SÀNS)/(MSÀNS)],w here S is the signal measured, NS is the nonspecific binding signal, and MS is the maximum binding signal observed with btVEGF 165 without tested compounds.
Cell culture:H UVEC were cultured in am edium supplemented with fetal bovine serum (FBS, 2%), l-glutamine (10 mm), heparin sulfate (0.75 UmL À1 ), VEGF (15 ng mL À1 ), EGF (5 ng mL À1 ), FGF2 (5 ng mL À1 ), IGF-I (15 ng mL À1 ), and ascorbic acid (50 mgmL À1 )a t 37 8C, in am oist atmosphere of 5% CO 2 .H UVEC were used for the experiment between passages 2to1 0.
In vitro morphogenesis assays on HUVEC:T oa ssess antiangiogenic activity,H UVEC (2.5 10 4 cells) were seeded in a2 4-well plate coated with 100 mL/well of Matrigel previously polymerized for 1h at 37 8C. Cells were then incubated for 5h at 37 8Ci namoist atmosphere of 5% CO 2 without or with tested compounds under either resting (cell cultured in EndoGRO medium alone, without FBS and all the growth factors) or stimulated conditions (addition of VEGF,1 0ngmL À1 ). Network formation was evaluated by phasecontrast microscopy using af luorescence microscope (Axiovert 40CFL, Carl Zeiss S.p.A.,M ilan, Italy). Network formation was finally quantified in terms of total length of the branches. For the purpose of the analysis, open ramifications were considered as branches. The total branch length (pixels) was quantified using the ImageJ image analysis software (http://rsbweb.nih.gov/ij/).
Statistical analysis:D ata are shown as means AE standard deviation (S.D.) unless indicated otherwise. Statistical significance of the differences was assessed by two-tailed Student's t test for paired data. Calculations were performed using ac ommercial software www.chemistryopen.org (GraphPad Prism version 5.00 for Windows, GraphPad Software, La Jolla, USA, www.graphpad.com).
